HTML Microdata document

This HTML5 document contains 952 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
rdfs	http://www.w3.org/2000/01/rdf-schema#
bibo	http://purl.org/ontology/bibo/
n6	http://pubannotation.org/docs/sourcedb/PMC/sourceid/
n8	http://togows.dbcls.jp/entry/pubmed/
xsdh	http://www.w3.org/2001/XMLSchema#
n3	http://purl.jp/bio/10/colil/id/
n10	http://dx.doi.org/
n2	http://purl.jp/bio/10/colil/ontology/201303#
n11	http://www.ncbi.nlm.nih.gov/pmc/articles/
n7	http://purl.org/spar/doco/
dc	http://purl.org/dc/elements/1.1/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#

Statements

Subject Item: n3:23994953
rdf:type: n2:CitationPaper n2:RelevantPaper n2:ReferencePaper
rdfs:seeAlso: n6:0 n8:23994953 n10:10.1038%2Fsrep02560 n11:0
bibo:cites: n3:12398892 n3:19380445 n3:19047104 n3:21037017 n3:23396055 n3:17541031 n3:22045191 n3:15314165 n3:21159609 n3:23172312 n3:19581933 n3:11059749 n3:16361555 n3:17548789 n3:20428808 n3:22992620 n3:16230409 n3:16637061 n3:21597390 n3:16286009 n3:17305535 n3:20713723 n3:20670944 n3:17344479 n3:23542356 n3:23091115 n3:21546539 n3:16424029 n3:17296734 n3:18568074 n3:17047074 n3:17201169 n3:22393284
n2:cocitationWith: n3:28686955 n3:22337149 n3:28368392 n3:27186512 n3:21168239 n3:17047074 n3:22824790 n3:23052255 n3:24893891 n3:16567498 n3:18093943 n3:28202511 n3:25512530 n3:27276215 n3:24556840 n3:24331411 n3:23344542 n3:15631989 n3:20371689 n3:17541031 n3:21502504 n3:19451168 n3:22773810 n3:16365168 n3:23548153 n3:24867695 n3:26271669 n3:12926355 n3:19244128 n3:11309385 n3:27123256 n3:19308067 n3:23172312 n3:20531305 n3:26554308 n3:23993685 n3:29892069 n3:22285168 n3:15289330 n3:22253230 n3:14506643 n3:24885194 n3:15737014 n3:25870145 n3:26004344 n3:26052929 n3:12767520 n3:17508028 n3:10655586 n3:19945376 n3:10655587 n3:25435948 n3:16014893 n3:17563753 n3:28137302 n3:23470965 n3:16931767 n3:30080294 n3:26579470 n3:26106584 n3:26473643 n3:18790742 n3:25749031 n3:29660364 n3:23619944 n3:23552882 n3:25157649 n3:18485877 n3:17346182 n3:19692680 n3:21597390 n3:19667264 n3:26324738 n3:24830724 n3:21810918 n3:22956644 n3:23916468 n3:22751098 n3:22736441 n3:9087425 n3:19487818 n3:19487819 n3:25402766 n3:25245764 n3:26298207 n3:22431711 n3:23535923 n3:22473773 n3:26282169 n3:20952506 n3:21866554 n3:18381457 n3:20129249 n3:26337161 n3:20682976 n3:24142872 n3:9593409 n3:28223169 n3:21376230 n3:23536707 n3:19229591 n3:20025614 n3:24971507 n3:17305535 n3:15210113 n3:26822829 n3:26265685 n3:28213007 n3:25115383 n3:25446090 n3:24047698 n3:16953219 n3:20807804 n3:12189386 n3:26405092 n3:27368099 n3:16639715 n3:25923550 n3:17463250 n3:25984556 n3:21296855 n3:10605625 n3:21483012 n3:25079552 n3:15619214 n3:15983400 n3:11526479 n3:20962592 n3:24458568 n3:23542356 n3:25617986 n3:26980747 n3:26789630 n3:23601239 n3:26959886 n3:21525039 n3:21430067 n3:23091115 n3:15728811 n3:24489728 n3:16600976 n3:22622641 n3:17296734 n3:11994736 n3:18568074 n3:15050915 n3:25042456 n3:25944486 n3:16467097 n3:16424029 n3:24846037
n2:hasRelevantBibliographicResourceOf: _:vb531234020 _:vb531234021 _:vb531234022 _:vb531234023 _:vb531234016 _:vb531234017 _:vb531234018 _:vb531234019 _:vb531234028 _:vb531234029 _:vb531234030 _:vb531234031 _:vb531234024 _:vb531234025 _:vb531234026 _:vb531234027 _:vb531234036 _:vb531234037 _:vb531234038 _:vb531234039 _:vb531234032 _:vb531234033 _:vb531234034 _:vb531234035 _:vb531234044 _:vb531234045 _:vb531234046 _:vb531234047 _:vb531234040 _:vb531234041 _:vb531234042 _:vb531234043 _:vb531233988 _:vb531233989 _:vb531233990 _:vb531233991 _:vb531233984 _:vb531233985 _:vb531233986 _:vb531233987 _:vb531233996 _:vb531233997 _:vb531233998 _:vb531233999 _:vb531233992 _:vb531233993 _:vb531233994 _:vb531233995 _:vb531234004 _:vb531234005 _:vb531234006 _:vb531234007 _:vb531234000 _:vb531234001 _:vb531234002 _:vb531234003 _:vb531234012 _:vb531234013 _:vb531234014 _:vb531234015 _:vb531234008 _:vb531234009 _:vb531234010 _:vb531234011 _:vb531233964 _:vb531233965 _:vb531233966 _:vb531233967 _:vb531233962 _:vb531233963 _:vb531233972 _:vb531233973 _:vb531233974 _:vb531233975 _:vb531233968 _:vb531233969 _:vb531233970 _:vb531233971 _:vb531233980 _:vb531233981 _:vb531233982 _:vb531233983 _:vb531233976 _:vb531233977 _:vb531233978 _:vb531233979 _:vb531234112 _:vb531234084 _:vb531234085 _:vb531234086 _:vb531234087 _:vb531234080 _:vb531234081 _:vb531234082 _:vb531234083 _:vb531234092 _:vb531234093 _:vb531234094 _:vb531234095 _:vb531234088 _:vb531234089 _:vb531234090 _:vb531234091 _:vb531234100 _:vb531234101 _:vb531234102 _:vb531234103 _:vb531234096 _:vb531234097 _:vb531234098 _:vb531234099 _:vb531234108 _:vb531234109 _:vb531234110 _:vb531234111 _:vb531234104 _:vb531234105 _:vb531234106 _:vb531234107 _:vb531234052 _:vb531234053 _:vb531234054 _:vb531234055 _:vb531234048 _:vb531234049 _:vb531234050 _:vb531234051 _:vb531234060 _:vb531234061 _:vb531234062 _:vb531234063 _:vb531234056 _:vb531234057 _:vb531234058 _:vb531234059 _:vb531234068 _:vb531234069 _:vb531234070 _:vb531234071 _:vb531234064 _:vb531234065 _:vb531234066 _:vb531234067 _:vb531234076 _:vb531234077 _:vb531234078 _:vb531234079 _:vb531234072 _:vb531234073 _:vb531234074 _:vb531234075
n2:pmcid: PMC0
bibo:doi: 10.1038%2Fsrep02560
n7:contains: _:vb24815000

Subject Item: _:vb24815000
rdf:type: n7:Section
dc:title: discussion
n7:contains: _:vb24815004 _:vb24815005 _:vb24815006 _:vb24815007 _:vb24815001 _:vb24815002 _:vb24815003 _:vb24815012 _:vb24815013 _:vb24815014 _:vb24815015 _:vb24815008 _:vb24815009 _:vb24815010 _:vb24815011 _:vb24815020 _:vb24815021 _:vb24815022 _:vb24815023 _:vb24815016 _:vb24815017 _:vb24815018 _:vb24815019 _:vb24815028 _:vb24815029 _:vb24815030 _:vb24815031 _:vb24815024 _:vb24815025 _:vb24815026 _:vb24815027 _:vb24815036 _:vb24815037 _:vb24815038 _:vb24815032 _:vb24815033 _:vb24815034 _:vb24815035

Subject Item: _:vb24815001
rdf:type: n2:Context
rdf:value: While preparing this manuscript, Cortot et al.>>31<< reported that PC-9-derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR T790M demonstrate a significantly activated IGF-1R signaling, and
n2:mentions: n3:23172312

Subject Item: _:vb24815002
rdf:type: n2:Context
rdf:value: that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with EGFR inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib>>32<<33. It should be noted that increased IGF-1R activation in erlotinib-refractory delE746-A750-mutated PC-9 cells occurred in our lab models independently of changes in IGF-binding proteins (IGFBPs) (data not shown).
n2:mentions: n3:19380445

Subject Item: _:vb24815003
rdf:type: n2:Context
rdf:value: that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with EGFR inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib>>3233<<. It should be noted that increased IGF-1R activation in erlotinib-refractory delE746-A750-mutated PC-9 cells occurred in our lab models independently of changes in IGF-binding proteins (IGFBPs) (data not shown).
n2:mentions: n3:19581933

Subject Item: _:vb24815004
rdf:type: n2:Context
rdf:value: Whereas earlier studies have demonstrated that a loss of IGFBP (IGFBP-3 and IGFBP-4) expression levels in tumor cells treated with EGFR TKIs activated IGF-1R signaling, which in turn mediated resistance to an EGFR antagonist>>20<<31, our analyses failed to detect significant changes in the secretion levels of IGFBPs in delE746-A750-mutated PC-9 cells with acquired resistance to erlotinib.
n2:mentions: n3:18568074

Subject Item: _:vb24815005
rdf:type: n2:Context
rdf:value: Whereas earlier studies have demonstrated that a loss of IGFBP (IGFBP-3 and IGFBP-4) expression levels in tumor cells treated with EGFR TKIs activated IGF-1R signaling, which in turn mediated resistance to an EGFR antagonist>>2031<<, our analyses failed to detect significant changes in the secretion levels of IGFBPs in delE746-A750-mutated PC-9 cells with acquired resistance to erlotinib.
n2:mentions: n3:23172312

Subject Item: _:vb24815006
rdf:type: n2:Context
rdf:value: NSCLC responses to IGF-1R inhibition revealed that intrinsic sensitivity to figitumumab, a monoclonal antibody against IGF-1R, was significantly related to the simultaneous occurrence of markers of the IGF-1R pathway in the EMT pathway>>34<<. Although it remains unclear whether high-levels of IGF-1R expression are directly associated with high IGF-1R kinase activity levels, IGF-1R is among a small group of oncogenes that can confer in vivo tumorigenicity when overexpressed
n2:mentions: n3:20670944

Subject Item: _:vb24815007
rdf:type: n2:Context
rdf:value: kinase activity levels, IGF-1R is among a small group of oncogenes that can confer in vivo tumorigenicity when overexpressed alone via IGFR-1R-mediated induction of the transcriptional repressor SNAIL and downregulation of E-cadherin>>35<<. Indeed, recent results from our laboratory have confirmed that regardless of erlotinib treatment, EMT-enriched erlotinib-resistant PC-9 tumor xenografts exhibited a significantly enhanced tumor engraftment and faster growth compared with
n2:mentions: n3:17296734

Subject Item: _:vb24815008
rdf:type: n2:Context
rdf:value: direct implication in the EMT phenomenon, EMT transcriptional drivers (e.g., SNAIL factors) can also regulate other cellular processes related to cell proliferation and survival, thus contributing to resistance to pro-apoptotic stresses>>36<<373839. Accordingly, we recently revealed that a significant reduction in tumor growth and dramatic gain in sensitivity to the growth-inhibitory effects of the anti-HER2 monoclonal antibody trastuzumab in vivo can be observed upon
n2:mentions: n3:12398892

Subject Item: _:vb24815009
rdf:type: n2:Context
rdf:value: implication in the EMT phenomenon, EMT transcriptional drivers (e.g., SNAIL factors) can also regulate other cellular processes related to cell proliferation and survival, thus contributing to resistance to pro-apoptotic stresses>>3637<<3839. Accordingly, we recently revealed that a significant reduction in tumor growth and dramatic gain in sensitivity to the growth-inhibitory effects of the anti-HER2 monoclonal antibody trastuzumab in vivo can be observed upon injection
n2:mentions: n3:15314165

Subject Item: _:vb24815010
rdf:type: n2:Context
rdf:value: implication in the EMT phenomenon, EMT transcriptional drivers (e.g., SNAIL factors) can also regulate other cellular processes related to cell proliferation and survival, thus contributing to resistance to pro-apoptotic stresses>>363738<<39. Accordingly, we recently revealed that a significant reduction in tumor growth and dramatic gain in sensitivity to the growth-inhibitory effects of the anti-HER2 monoclonal antibody trastuzumab in vivo can be observed upon injection of
n2:mentions: n3:16286009

Subject Item: _:vb24815011
rdf:type: n2:Context
rdf:value: implication in the EMT phenomenon, EMT transcriptional drivers (e.g., SNAIL factors) can also regulate other cellular processes related to cell proliferation and survival, thus contributing to resistance to pro-apoptotic stresses>>36373839<<. Accordingly, we recently revealed that a significant reduction in tumor growth and dramatic gain in sensitivity to the growth-inhibitory effects of the anti-HER2 monoclonal antibody trastuzumab in vivo can be observed upon injection of
n2:mentions: n3:17344479

Subject Item: _:vb24815012
rdf:type: n2:Context
rdf:value: a significant reduction in tumor growth and dramatic gain in sensitivity to the growth-inhibitory effects of the anti-HER2 monoclonal antibody trastuzumab in vivo can be observed upon injection of SLUG knocked-down cells into nude mice>>40<<. The promotion of cell survival as a primary function of EMT factors such as SLUG, which can rescue cells from apoptosis by repressing pro-apoptotic factors that otherwise would promote cell death during a partial EMT, is strongly
n2:mentions: n3:22992620

Subject Item: _:vb24815013
rdf:type: n2:Context
rdf:value: Using erlotinib hyper-resistant cells established from H1650 cells, which are EGFR mutant but unresponsive to erlotinib due to PTEN deletion, Yao et al>>41<< were pioneers at uncovering the existence of a TGFβ-driven subpopulation of NSCLC cells intrinsically resistant to erlotinib that display features suggestive of EMT.
n2:mentions: n3:20713723

Subject Item: _:vb24815014
rdf:type: n2:Context
rdf:value: of NSCLC cells intrinsically resistant to erlotinib that display features suggestive of EMT. Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749, A750P mutation in EGFR exon 19, Suda et al.>>29<< established that mesenchymal status, not a specific oncogenic-activated protein, could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib.
n2:mentions: n3:21597390

Subject Item: _:vb24815015
rdf:type: n2:Context
rdf:value: mutation in EGFR exon 19, Suda et al.29 established that mesenchymal status, not a specific oncogenic-activated protein, could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib. More recently, Chang et al.>>42<< confirmed that in the absence of the common second-site EGFR mutation T790M or MET amplification, acquired resistance to gefitinib occurs in EGFR-mutated PC9 cells that have undergone EMT.
n2:mentions: n3:21037017

Subject Item: _:vb24815016
rdf:type: n2:Context
rdf:value: Importantly, SLUG expression in clinical samples was significantly higher after the development of acquired resistance to EGFR TKIs than in treatment-naïve samples>>42<<.
n2:mentions: n3:21037017

Subject Item: _:vb24815017
rdf:type: n2:Context
rdf:value: Earlier studies have suggested an active involvement of EMT in resistance to EGFR TKIs>>25<<274344, and accordingly, E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of gefitinib27.
n2:mentions: n3:16230409

Subject Item: _:vb24815018
rdf:type: n2:Context
rdf:value: Earlier studies have suggested an active involvement of EMT in resistance to EGFR TKIs>>2527<<4344, and accordingly, E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of gefitinib27.
n2:mentions: n3:16361555

Subject Item: _:vb24815019
rdf:type: n2:Context
rdf:value: Earlier studies have suggested an active involvement of EMT in resistance to EGFR TKIs>>252743<<44, and accordingly, E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of gefitinib27.
n2:mentions: n3:17541031

Subject Item: _:vb24815020
rdf:type: n2:Context
rdf:value: Earlier studies have suggested an active involvement of EMT in resistance to EGFR TKIs>>25274344<<, and accordingly, E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of gefitinib27.
n2:mentions: n3:16424029

Subject Item: _:vb24815021
rdf:type: n2:Context
rdf:value: Earlier studies have suggested an active involvement of EMT in resistance to EGFR TKIs25274344, and accordingly, E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of gefitinib>>27<<. However, it should be noted that these studies were largely based on NSCLC cells expressing wild-type EGFR; therefore, these studies did not mimic clinical usage of EGFR TKIs because EGFR wild-type NSCLC cells are intrinsically resistant
n2:mentions: n3:16361555

Subject Item: _:vb24815022
rdf:type: n2:Context
rdf:value: A microRNA gene expression signature targeting EMT has been recently shown to predict response to erlotinib>>45<<. Byers et al.46 recently developed a robust EMT signature that highlights different drug responsiveness patterns for epithelial and mesenchymal NSCLC cells and can predict resistance to EGFR TKIs regardless of EGFR mutation status. It
n2:mentions: n3:22045191

Subject Item: _:vb24815023
rdf:type: n2:Context
rdf:value: loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status. A microRNA gene expression signature targeting EMT has been recently shown to predict response to erlotinib45. Byers et al.>>46<< recently developed a robust EMT signature that highlights different drug responsiveness patterns for epithelial and mesenchymal NSCLC cells and can predict resistance to EGFR TKIs regardless of EGFR mutation status.
n2:mentions: n3:23091115

Subject Item: _:vb24815024
rdf:type: n2:Context
rdf:value: that a “mesenchymal transition signature” likely reflects a reversible process in which the mesenchymal markers may dynamically appear and disappear depending on intrinsic (i.e., cell autonomous) and/or microenvironmental signals>>41<<. Consequently, the potential use of EMT-like predictive signatures would have high selectively but not might have the sensitivity to predict acquired resistance to erlotinib.
n2:mentions: n3:20713723

Subject Item: _:vb24815025
rdf:type: n2:Context
rdf:value: In this regard, it is worth noting that a landmark study showing that the addition of silibinin, which is the active constituent of silymarin isolated from the dried fruits of milk thistle (Silybum marianum) plant>>47<<484950, to EGFR TKIs drastically suppresses tumor growth in primary and acquired-resistance cells with the EGFR T790M mutation51 may open a new therapeutic avenue to clinically manage EMT-driven acquired resistance to erlotinib.
n2:mentions: n3:17548789

Subject Item: _:vb24815026
rdf:type: n2:Context
rdf:value: In this regard, it is worth noting that a landmark study showing that the addition of silibinin, which is the active constituent of silymarin isolated from the dried fruits of milk thistle (Silybum marianum) plant>>4748<<4950, to EGFR TKIs drastically suppresses tumor growth in primary and acquired-resistance cells with the EGFR T790M mutation51 may open a new therapeutic avenue to clinically manage EMT-driven acquired resistance to erlotinib.
n2:mentions: n3:17305535

Subject Item: _:vb24815027
rdf:type: n2:Context
rdf:value: In this regard, it is worth noting that a landmark study showing that the addition of silibinin, which is the active constituent of silymarin isolated from the dried fruits of milk thistle (Silybum marianum) plant>>474849<<50, to EGFR TKIs drastically suppresses tumor growth in primary and acquired-resistance cells with the EGFR T790M mutation51 may open a new therapeutic avenue to clinically manage EMT-driven acquired resistance to erlotinib.
n2:mentions: n3:17201169

Subject Item: _:vb24815028
rdf:type: n2:Context
rdf:value: In this regard, it is worth noting that a landmark study showing that the addition of silibinin, which is the active constituent of silymarin isolated from the dried fruits of milk thistle (Silybum marianum) plant>>47484950<<, to EGFR TKIs drastically suppresses tumor growth in primary and acquired-resistance cells with the EGFR T790M mutation51 may open a new therapeutic avenue to clinically manage EMT-driven acquired resistance to erlotinib.
n2:mentions: n3:16637061

Subject Item: _:vb24815029
rdf:type: n2:Context
rdf:value: the active constituent of silymarin isolated from the dried fruits of milk thistle (Silybum marianum) plant47484950, to EGFR TKIs drastically suppresses tumor growth in primary and acquired-resistance cells with the EGFR T790M mutation>>51<< may open a new therapeutic avenue to clinically manage EMT-driven acquired resistance to erlotinib.
n2:mentions: n3:21159609

Subject Item: _:vb24815030
rdf:type: n2:Context
rdf:value: Silibinin appears to operate as a potent natural agent leading to the reversal of EMT by decreasing the levels of key EMT TFs (e.g., SLUG) and increasing the expression levels of E-cadherin>>52<<5354. Silibinin has been shown to reduce IGF-1R phosphorylation, indicating an inhibitory effect on the IGF-1R-mediated signaling pathway in cancer cells5556. Through using a milk thistle extract rich in silybin meglumine, a commercially
n2:mentions: n3:19047104

Subject Item: _:vb24815031
rdf:type: n2:Context
rdf:value: Silibinin appears to operate as a potent natural agent leading to the reversal of EMT by decreasing the levels of key EMT TFs (e.g., SLUG) and increasing the expression levels of E-cadherin>>5253<<54. Silibinin has been shown to reduce IGF-1R phosphorylation, indicating an inhibitory effect on the IGF-1R-mediated signaling pathway in cancer cells5556. Through using a milk thistle extract rich in silybin meglumine, a commercially
n2:mentions: n3:20428808

Subject Item: _:vb24815032
rdf:type: n2:Context
rdf:value: Silibinin appears to operate as a potent natural agent leading to the reversal of EMT by decreasing the levels of key EMT TFs (e.g., SLUG) and increasing the expression levels of E-cadherin>>525354<<. Silibinin has been shown to reduce IGF-1R phosphorylation, indicating an inhibitory effect on the IGF-1R-mediated signaling pathway in cancer cells5556. Through using a milk thistle extract rich in silybin meglumine, a commercially used
n2:mentions: n3:21546539

Subject Item: _:vb24815033
rdf:type: n2:Context
rdf:value: Silibinin has been shown to reduce IGF-1R phosphorylation, indicating an inhibitory effect on the IGF-1R-mediated signaling pathway in cancer cells>>55<<56. Through using a milk thistle extract rich in silybin meglumine, a commercially used water-soluble form of silibinin57, we are currently testing whether the anti-IGF-1R/EMT activity of silibinin can translate into the reversal of
n2:mentions: n3:11059749

Subject Item: _:vb24815034
rdf:type: n2:Context
rdf:value: Silibinin has been shown to reduce IGF-1R phosphorylation, indicating an inhibitory effect on the IGF-1R-mediated signaling pathway in cancer cells>>5556<<. Through using a milk thistle extract rich in silybin meglumine, a commercially used water-soluble form of silibinin57, we are currently testing whether the anti-IGF-1R/EMT activity of silibinin can translate into the reversal of acquired
n2:mentions: n3:23396055

Subject Item: _:vb24815035
rdf:type: n2:Context
rdf:value: Through using a milk thistle extract rich in silybin meglumine, a commercially used water-soluble form of silibinin>>57<<, we are currently testing whether the anti-IGF-1R/EMT activity of silibinin can translate into the reversal of acquired resistance to EGFR TKIs in animal models.
n2:mentions: n3:22393284

Subject Item: _:vb24815036
rdf:type: n2:Context
rdf:value: A dual targeting of IGF-1R and EMT might be crucial to prevent and/or circumvent acquired resistance to erlotinib in EGFR-mutated cells because, although early studies by Morgillo et al.>>58<< provided evidence that erlotinib induces heterodimerization of EGFR/IGF-1R, we failed to observe either co-localization of the phospho-active forms of EGFR and IGF-1R or changes in the phosphorylation status of EGFR upon pharmacological
n2:mentions: n3:17047074

Subject Item: _:vb24815037
rdf:type: n2:Context
rdf:value: During the preparation of this manuscript, Shien et al.>>59<< reported that acquired resistance to the EGFR inhibitor gefitinib was associated with a manifestation of stem cell-like properties in EGFR-mutated NSCLC cells, including EMT features, overexpression of the stem cell-marker aldehyde
n2:mentions: n3:23542356

Subject Item: _:vb24815038
rdf:type: n2:Context
rdf:value: While the majority of previously reported cells that acquired resistance to the EGFR TKIs gefitinib and erlotinib were established with stepwise escalation of the EGFR TKI concentration, when Shien et al.>>59<< established gefitinib-resistant cells with both the stepwise escalation method and the high-concentration exposure method, they observed that the manner of exposure to the EGFR TKI notable influenced the mechanism of acquired resistance;
n2:mentions: n3:23542356

Subject Item: _:vb531233962
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 8
n2:hasRelevantPaperId: n3:17463250

Subject Item: _:vb531233963
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 7
n2:hasRelevantPaperId: n3:23091115

Subject Item: _:vb531233964
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 6
n2:hasRelevantPaperId: n3:18568074

Subject Item: _:vb531233965
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 6
n2:hasRelevantPaperId: n3:23470965

Subject Item: _:vb531233966
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 6
n2:hasRelevantPaperId: n3:23172312

Subject Item: _:vb531233967
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:23552882

Subject Item: _:vb531233968
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:22773810

Subject Item: _:vb531233969
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:20129249

Subject Item: _:vb531233970
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:24458568

Subject Item: _:vb531233971
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:18485877

Subject Item: _:vb531233972
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 5
n2:hasRelevantPaperId: n3:22751098

Subject Item: _:vb531233973
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:25749031

Subject Item: _:vb531233974
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:18381457

Subject Item: _:vb531233975
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:24556840

Subject Item: _:vb531233976
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:19945376

Subject Item: _:vb531233977
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:23542356

Subject Item: _:vb531233978
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:15728811

Subject Item: _:vb531233979
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:26554308

Subject Item: _:vb531233980
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:23601239

Subject Item: _:vb531233981
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:17508028

Subject Item: _:vb531233982
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:17296734

Subject Item: _:vb531233983
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:12189386

Subject Item: _:vb531233984
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:23619944

Subject Item: _:vb531233985
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:27186512

Subject Item: _:vb531233986
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:17047074

Subject Item: _:vb531233987
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:25617986

Subject Item: _:vb531233988
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:19487818

Subject Item: _:vb531233989
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:25446090

Subject Item: _:vb531233990
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:24893891

Subject Item: _:vb531233991
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:24489728

Subject Item: _:vb531233992
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:20531305

Subject Item: _:vb531233993
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:10655586

Subject Item: _:vb531233994
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:22285168

Subject Item: _:vb531233995
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:26282169

Subject Item: _:vb531233996
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:21597390

Subject Item: _:vb531233997
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:25984556

Subject Item: _:vb531233998
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:16424029

Subject Item: _:vb531233999
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:26106584

Subject Item: _:vb531234000
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:11526479

Subject Item: _:vb531234001
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26789630

Subject Item: _:vb531234002
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:14506643

Subject Item: _:vb531234003
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24142872

Subject Item: _:vb531234004
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26052929

Subject Item: _:vb531234005
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21502504

Subject Item: _:vb531234006
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23344542

Subject Item: _:vb531234007
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24867695

Subject Item: _:vb531234008
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25512530

Subject Item: _:vb531234009
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26405092

Subject Item: _:vb531234010
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22253230

Subject Item: _:vb531234011
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26473643

Subject Item: _:vb531234012
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15619214

Subject Item: _:vb531234013
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:18093943

Subject Item: _:vb531234014
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23993685

Subject Item: _:vb531234015
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16567498

Subject Item: _:vb531234016
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21525039

Subject Item: _:vb531234017
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24047698

Subject Item: _:vb531234018
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25944486

Subject Item: _:vb531234019
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21866554

Subject Item: _:vb531234020
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25870145

Subject Item: _:vb531234021
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:12767520

Subject Item: _:vb531234022
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:12926355

Subject Item: _:vb531234023
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22956644

Subject Item: _:vb531234024
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15210113

Subject Item: _:vb531234025
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15631989

Subject Item: _:vb531234026
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16931767

Subject Item: _:vb531234027
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17305535

Subject Item: _:vb531234028
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19229591

Subject Item: _:vb531234029
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22337149

Subject Item: _:vb531234030
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25245764

Subject Item: _:vb531234031
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26324738

Subject Item: _:vb531234032
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28202511

Subject Item: _:vb531234033
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16600976

Subject Item: _:vb531234034
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22622641

Subject Item: _:vb531234035
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24885194

Subject Item: _:vb531234036
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15050915

Subject Item: _:vb531234037
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17541031

Subject Item: _:vb531234038
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21376230

Subject Item: _:vb531234039
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22736441

Subject Item: _:vb531234040
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26822829

Subject Item: _:vb531234041
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25435948

Subject Item: _:vb531234042
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28213007

Subject Item: _:vb531234043
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20025614

Subject Item: _:vb531234044
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20371689

Subject Item: _:vb531234045
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20952506

Subject Item: _:vb531234046
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23535923

Subject Item: _:vb531234047
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20682976

Subject Item: _:vb531234048
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25115383

Subject Item: _:vb531234049
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26004344

Subject Item: _:vb531234050
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26265685

Subject Item: _:vb531234051
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16467097

Subject Item: _:vb531234052
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16953219

Subject Item: _:vb531234053
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19244128

Subject Item: _:vb531234054
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24830724

Subject Item: _:vb531234055
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28223169

Subject Item: _:vb531234056
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15289330

Subject Item: _:vb531234057
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19308067

Subject Item: _:vb531234058
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23536707

Subject Item: _:vb531234059
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25079552

Subject Item: _:vb531234060
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15983400

Subject Item: _:vb531234061
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17563753

Subject Item: _:vb531234062
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22473773

Subject Item: _:vb531234063
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28137302

Subject Item: _:vb531234064
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:10605625

Subject Item: _:vb531234065
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:11994736

Subject Item: _:vb531234066
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19487819

Subject Item: _:vb531234067
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21168239

Subject Item: _:vb531234068
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23052255

Subject Item: _:vb531234069
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24331411

Subject Item: _:vb531234070
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26337161

Subject Item: _:vb531234071
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16365168

Subject Item: _:vb531234072
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26959886

Subject Item: _:vb531234073
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20962592

Subject Item: _:vb531234074
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23548153

Subject Item: _:vb531234075
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:30080294

Subject Item: _:vb531234076
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:18790742

Subject Item: _:vb531234077
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20807804

Subject Item: _:vb531234078
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21430067

Subject Item: _:vb531234079
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21810918

Subject Item: _:vb531234080
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24971507

Subject Item: _:vb531234081
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26271669

Subject Item: _:vb531234082
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:10655587

Subject Item: _:vb531234083
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21483012

Subject Item: _:vb531234084
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24846037

Subject Item: _:vb531234085
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27368099

Subject Item: _:vb531234086
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:29892069

Subject Item: _:vb531234087
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16639715

Subject Item: _:vb531234088
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22431711

Subject Item: _:vb531234089
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27123256

Subject Item: _:vb531234090
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28368392

Subject Item: _:vb531234091
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:16014893

Subject Item: _:vb531234092
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25157649

Subject Item: _:vb531234093
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25402766

Subject Item: _:vb531234094
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:29660364

Subject Item: _:vb531234095
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:9593409

Subject Item: _:vb531234096
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19692680

Subject Item: _:vb531234097
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26980747

Subject Item: _:vb531234098
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21296855

Subject Item: _:vb531234099
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23916468

Subject Item: _:vb531234100
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:9087425

Subject Item: _:vb531234101
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19451168

Subject Item: _:vb531234102
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:19667264

Subject Item: _:vb531234103
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26298207

Subject Item: _:vb531234104
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26579470

Subject Item: _:vb531234105
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27276215

Subject Item: _:vb531234106
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:11309385

Subject Item: _:vb531234107
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:15737014

Subject Item: _:vb531234108
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17346182

Subject Item: _:vb531234109
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22824790

Subject Item: _:vb531234110
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25042456

Subject Item: _:vb531234111
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25923550

Subject Item: _:vb531234112
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28686955